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Background: The positive influences of glucagon-like peptide-1 (GLP-1) on blood glucose homeostasis, appetite
sensations, and food intake provide a strong rationale for its therapeutic potential in the nutritional management of
obesity and type 2 diabetes.
Aim: To summarize GLP-1 physiology and the nutritional modulation of its secretion in the context of obesity and
type 2 diabetes management.
Findings: GLP-1 is mainly synthesized and secreted by enteroendocrine L-cells of the gastrointestinal tract. Its
secretion is partly mediated by the direct nutrient sensing by G-protein coupled receptors which specifically bind
to monosaccharides, peptides and amino-acids, monounsaturated and polyunsaturated fatty acids as well as to
short chain fatty acids. Foods rich in these nutrients, such as high-fiber grain products, nuts, avocados and eggs
also seem to influence GLP-1 secretion and may thus promote associated beneficial outcomes in healthy
individuals as well as individuals with type 2 diabetes or with other metabolic disturbances.
Conclusion: The stimulation of endogenous GLP-1 secretion by manipulating the composition of the diet may be
a relevant strategy for obesity and type 2 diabetes management. A better understanding of the dose-dependent
effects as well as the synergistic effects of nutrients and whole foods is needed in order to develop
recommendations to appropriately modify the diet to enhance GLP-1 beneficial effects.
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Type 2 diabetes (T2D) is a major public health concern due
to its pandemic occurrence and its association with several
physical and psychological comorbidities [1, 2], as well as
with a decreased quality of life [3]. It is widely accepted that
obesity, especially excessive fat accumulation in the abdom-
inal area, is the most important predictor of T2D develop-
ment. Indeed, it is estimated that 60 to 90% of T2D
incidence is related to excessive weight gain and obesity [4].
After the onset of T2D, obesity also contributes to increas-
ing the risks of comorbidities and overall mortality rates [5].
The global prevalence of overweight and obesity is expected
to reach 57.8% by 2030 [6]. Following a similar trend, the* Correspondence: igiroux@uottawa.ca
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Nutrition, along with physical activity and behavioural
changes, are cornerstones of obesity and T2D management.
Weight loss is induced by a state of sustained negative en-
ergy balance, which almost inevitably involves a reduction
of energy intake [8]. From a purely thermodynamic perspec-
tive, a decrease in energy intake results in weight loss re-
gardless of the type of dietary modifications through which
it is achieved. Nonetheless, weight maintenance and im-
provements in cardiometabolic biomarkers are significantly
impacted by the composition of the diet (i.e. macro- and
micronutrient contents) [8]. One potential mechanism by
which diet composition can influence these outcomes is
through its influence on the secretion of gastrointestinal
(GI) peptide hormones, including that of glucagon-like
peptide-1 (GLP-1) [9]. The latter has been associated with a
reduction of appetite and food intake, and appears tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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the pancreas and the central nervous system [10].
The secretion of GLP-1 is partly mediated by the bind-
ing of nutrients to G-protein coupled receptors (GPCRs)
expressed by enteroendocrine GI cells [11]. Therefore,
manipulating the diet in a way to promote interactions
with these receptors could increase GLP-1 secretion and
enhance its beneficial effects [11]. This review focuses
on GLP-1 physiology and the nutritional modulation of
its secretion from enteroendocrine GI cells in the con-
text of obesity and T2D management. It presents recent
evidence on possible mechanisms by which specific
foods, as well as nutrients and their by-products, could
increase GLP-1 secretion, and subsequently influence
appetite, food intake, and blood glucose control.
Glucagon-like peptide-1 in the gut-brain-pancreas
axis
Synthesis, secretion, and metabolism
The GI tract accomplishes several functions, namely the
digestion of food, the absorption of nutrients, and the
secretion of digestive juices, mucus, and peptide hor-
mones. The epithelium of the GI wall is composed of
several cell types, including enteroendocrine cells which
are a key component of the gut-brain-pancreas axis [12].
On their apical surface, enteroendocrine cells possess
microvilli expressing several GPCRs that are binding to
nutrients and other substrates present in the GI lumen
[12]. Enteroendocrine cells can be divided into several
subcategories depending on their distribution through-
out the GI tract, their GPCRs’ expression and their
secretory profile. GLP-1 is synthesized and secreted by
enteroendocrine L-cells which are expressed over a large
portion of the GI tract, starting in the proximal small in-
testine and progressively increasing in density down to
the distal part of the colon. GLP-1 is stored in secretory
granules of L-cells until its secretion is triggered, and
then uses endocrine and neuronal routes to exert its
functions in the pancreas and central nervous system
[10]. In addition to L-cells, GLP-1 is synthesized to a
lesser extent by neurons of the nucleus tractus solitarius
(NTS) of the brainstem [13, 14].
GLP-1 is produced in two major active forms, namely
GLP-1 (7-36 amide) and GLP-1 (7-37 amide), and is result-
ing from the differential processing of its precursor proglu-
cagon [10]. Its synthesis appears to be attributed to tissue-
specific expression of pro-hormone convertase 1 and 3
which cleave proglucagon [15]. Proglucagon is a 160-amino
acid inactive precursor of several peptide hormones, includ-
ing glucagon, oxyntomodulin and GLP-1 [16]. Proglucagon
encoding gene is expressed in the intestine, the pancreas, as
well as the central nervous system [16]. Several studies have
confirmed that this gene produces identical messenger
ribonucleic acid (mRNA) transcripts in these majorexpression sites, but is translated and processed differently,
thus producing different bioactive peptides depending on
the expressing tissue [17–19].
In humans, blood concentrations of GLP-1 generally
range between 5 pmol/L and 15 pmol/L in fasting state
and increase two- to four-folds after food ingestion [10].
More specifically, GLP-1 blood concentrations rise
within 15 minutes after food ingestion and reach a pick
after approximately 60 minutes [10]. In the second hour,
GLP-1 concentrations start to decrease gradually until
the next prandial episode [10]. Postprandial GLP-1 se-
cretion is influenced by both neuroendocrine and nutri-
tional factors, and exhibits a two-phase release profile
that is in fact very similar to that of insulin. The initial
phase of its secretion, which is detectable 10 to 15 mi-
nutes after food ingestion, is thought to be mostly influ-
enced by neuroendocrine factors, and, to a lesser extent,
by the interaction of nutrients with L-cells in the prox-
imal small intestine. Conversely, the second phase of
GLP-1 secretion, which occurs 30 to 60 minutes post-
prandially, is mostly influenced by the arrival of nutri-
ents in the distal part of the small intestine and the
colon [20]. Nutrients and their by-products bind to
GPCRs and activate intracellular pathways that ultim-
ately trigger GLP-1 exocytosis from L-cells’ secretory
granules [10]. When secreted, GLP-1 can activate vagal
afferent neural fibres, as well as diffuse into nearby capil-
laries and then reach the systemic circulation through
the portal vein [10]. In the bloodstream, GLP-1 is highly
susceptible to the catalytic activity of the enzyme
dipeptidyl-peptidase IV (DPP-IV). The latter cleaves two
NH2-terminal amino acids of the active forms of GLP-1
(i.e. 7-36 amide, 7-37 amide) leading to the production
of their biologically inactive forms (i.e. 9-36 amide, 9-37
amide) [21–23]. As a result, GLP-1’s half-life is very
short – about 1 to 2 min [22, 23]. Animal and in vitro
studies have shown that less than 25% of the newly se-
creted bioactive GLP-1 reaches the liver intact [22, 23].
Further catalytic activities take place in the liver, and
consequently, only approximately 10-15% of the newly
secreted GLP-1 reaches the systemic circulation in its
active forms [22, 23].
Action in the pancreas
One of the best-known and probably most important ef-
fects of GLP-1 is its ability to stimulate insulin secretion in
response to carbohydrate consumption [24–27]. In pancre-
atic β-cells, GLP-1 activates intracellular pathways that
increase intracellular calcium concentrations and subse-
quently leads to insulin exocytosis from secretory granules
[24, 25]. GLP-1 has also been shown to promote insulin
gene transcription and biosynthesis [28]. GLP-1 seems to
be responsible for nearly half of the total postprandial insu-
lin secretion [29]. This process, known under the name of
Bodnaruc et al. Nutrition & Metabolism  (2016) 13:92 Page 3 of 16“incretin effect”, is defined as the differential augmentation
in insulin secretion observed after oral glucose intake, com-
pared to intravenous glucose administration resulting in the
same blood glucose concentrations [30].
GLP-1 is partly fulfilling its actions in pancreatic β-
cells through an endocrine pathway by directly interact-
ing with its receptors (GLP-1Rs). Indeed, competitive in-
hibition of GLP-1Rs of pancreatic β-cells in rodents and
humans resulted in a significant reduction of insulin se-
cretion, as well as in impaired glucose tolerance [26, 27].
Nonetheless, the glucose-lowering effects of GLP-1 are
not solely related to its insulinotropic effect, but also to
its strong inhibition of glucagon secretion [10, 31]. This
effect seems to be partly mediated by the increased insu-
lin and somatostatin secretion from pancreatic islets oc-
curring during the postprandial period, as well as by
GLP-1 direct interaction with its receptors on pancreatic
α-cells [32–34]. In rodents, prolonged administration of
GLP-1 also appears to promote pancreatic β-cell growth
by increasing their proliferation and decreasing apop-
tosis [35–38].Action in the central nervous system
In addition to its action in the pancreas, GLP-1 plays a
role in both homeostatic and non-homeostatic regulations
of food intake, which occur in distinct areas of the central
nervous system [39, 40]. The homeostatic regulation of
food intake, related to short- and long-term energy status,
is mainly taking place in the hypothalamus and NTS,
areas which convey and integrate numerous peripheral
signals [39, 40]. The hypothalamus contains several inter-
connected nuclei, including the arcuate nucleus (ARC),
the paraventricular nucleus (PVN), as well as the dorso-
medial nucleus (DMN) [39, 40]. Due to its anatomical
position, the ARC plays a critical role in transmitting per-
ipheral information related to energy and nutrient status
to other central structures. Indeed, the ARC is situated in
the medio-basal area of the hypothalamus, where the
blood-brain barrier is highly permeable, and thus likely
has a greater exposition to circulating factors [39]. The
ARC contains two distinct populations of neurons: 1) the
orexigenic neuropeptide Y (NPY) and agouti-related pep-
tide (AgRP) expressing neurons, and 2) the anorexigenic
pro-opiomelanocortine (POMC), as well as cocaine and
amphetamine-regulated transcript (CART) expressing
neurons [39, 40]. Additionally, POMC is a precursor of
the α-melanocyte stimulating hormone (α-MSH), a neuro-
peptide with potent anorexigenic effects [39, 40]. Upon re-
lease, POMC and α-MSH activate neurons of the PVN,
which inhibits food intake [39, 40]. Conversely, by inhibit-
ing PVN neurons’ activation, NPY and AgRP stimulate
food intake [39, 40]. Opposite to the PVN, DMN neurons
are activated by NPY and AgRP, promoting food intake,and are inhibited by POMC and α-MSH, reducing food
intake [39, 40].
GLP-1Rs are widely expressed in the hypothalamus,
with the highest expression being described to be in
POMC/CART neurons of the ARC, followed by DMN
neurons [13, 14, 41–44]. A small quantity of GLP-1 ap-
pears to diffuse through the blood-brain barrier and dir-
ectly bind to its receptors on POMC/CART and NPY/
AgRP neurons [45]. In rodents, the peripheral adminis-
tration of a GLP-1 analogue has been shown to directly
activate neurotransmission in POMC/CART neurons,
while exerting an inhibitory action in NPY/AgRP neu-
rons [46, 47]. Nonetheless, in reason of its short half-life,
endogenous GLP-1 released from L-cells is likely mostly
acting on the central nervous system by indirectly stimu-
lating neurons of the NTS and ARC via the activation of
vagal afferent neurons [48]. Indeed, GLP-1Rs have been
identified on neurons of the nodose ganglion of the
vagus nerve [43, 49], and the importance of this pathway
in the regulation of food intake has been confirmed in
rats, where vagal deafferentation decreased the effects of
intraperitoneally administered GLP-1 [50, 51]. While the
exact mechanisms and their relative contributions to the
observed effects remain to be fully elucidated, the GLP-
1’s implication in the homeostatic regulation of food in-
take is well established. In rodents, acute intraperitoneal,
subcutaneous or intravenous administration of GLP-1
and GLP-1 analogues have constantly been shown to re-
duced meal size, as well as cumulative food and energy
intakes [51–56]. Similarly, in humans, acute intravenous
administration of GLP-1 and GLP-1 analogues decreased
appetite, hunger and food intake, and increased fullness
and satiety sensations [57–62].
In addition to physiological energy needs, food intake is
driven by non-homeostatic central pathways involved in re-
ward processing and reward-motivated behaviours [63, 64].
The palatability of food is a crucial determinant of the deci-
sion to eat. As a result, highly palatable food, typically high
in energy, lipids, and simple carbohydrates, can trigger food
intake in the absence of physiological energy needs [63, 64].
Several central structures, such as the orbitofrontal cortex,
insula, amygdala, and striatum play an important role in
the processing and evaluation of food cues [65]. Increased
activation of these areas of the central nervous system in
response to visual and olfactory food cues (referred to as
“anticipatory food reward”) is associated with increased
craving for highly palatable foods [66, 67]. Furthermore,
upon food ingestion, dopaminergic neurons send projec-
tions from the ventral tegmental area to the nucleus ac-
cumbens and other forebrain areas [63, 64]. Dopamine
release in these areas of the brain is well correlated with
meal pleasantness in healthy individuals with a normal
body mass index [68]. Activation of these areas in response
to food consumption is referred to as “consummatory food
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with compensatory overeating [65–67, 69, 70]. GLP-1Rs
have been identified in areas of the brain involved in antici-
patory and consummatory food reward processing, and
neurons of the NTS also share dense neuronal connections
with these areas [71, 72]. Recent pre-clinical and clinical
studies suggest a role of GLP-1 in the modulation of food
reward processing. More specifically, the exogenous admin-
istration of GLP-1 and GLP-1 analogues appears to influ-
ence dopamine neurotransmission in several central areas,
and has been associated with decreased anticipatory food
reward, increased consummatory food reward and de-
creased intake of hyperpalatable foods [65, 69, 70, 73–77].
Glucagon-like peptide-1 as a target for obesity
and type 2 diabetes management
The positive influences of GLP-1 on many metabolic dis-
turbances associated with T2D, as well as key determinants
of weight loss and weight maintenance, make it a thera-
peutic target with good potential. GLP-1 has been studied
in relation to obesity and T2D pathophysiology and treat-
ment. While few studies have shown contradictory results,
it is generally well accepted that obesity and metabolic
changes occurring with the development of T2D are associ-
ated with a decline in the postprandial secretion of GLP-1
from L-cells [78–83]. Overtime, this change in GLP-1’s se-
cretion can contribute to further weight gain and adversely
impact T2D progression. As a potential strategy to enhance
GLP-1actions, several researchers have investigated the
metabolic effects of intravenous administration of GLP-1
analogues. Interestingly, when receiving the same dose of a
GLP-1 analogue, individuals with obesity and T2D exhib-
ited metabolic and appetite responses that were very similar
to their healthy counterparts [57–59, 62, 84, 85]. This find-
ing suggests that sensibility to GLP-1’s action is maintained,
which is contrary to several other peptide hormones in-
volved in energy and blood glucose homeostasis [86, 87].
Consequently, targeting GLP-1Rs’ activation with GLP-1
analogues and increasing GLP-1 half-life in the bloodstream
became an area of interest for the management of obesity
and T2D. This led to the development of two classes of
pharmacologic agents, namely GLP-1Rs agonists and DDP-
IV inhibitors [88, 89]. GLP-1Rs agonists are widely used for
blood glucose management in individuals with T2D and
have recently been approved to use for weight management
in the United States [88–90]. Similarly, DDP-IV inhibitors
are used alone or in combination with other pharmaceut-
ical agents to inhibit the catabolic deactivation of endogen-
ous GLP-1 [88, 89]. Compared to other commonly used
antihyperglycemic drugs such as sulfonylureas and thiazoli-
dinedione, pharmaceutical agents targeting GLP-1’s action
are associated with lower risks of hypoglycaemia, and have
the advantage of promoting weight loss as well as poten-
tially preventing, or at least delaying the progressivedecrease in pancreatic β-cell function which generally re-
quires increasing drug dosage [35–38, 89, 91]. Most fre-
quent side effects reported with the use of these agents
include GI discomfort, nausea and vomiting [88, 89].
Another relevant, yet less studied, strategy to increase
GLP-1’s action is to promote its endogenous secretion
from L-cells. This could potentially be achieved through
pharmacological and dietary approaches. The main critic
of dietary approaches is that dietary changes may not
lead to a sufficient increase in GLP-1 blood concentra-
tion to promote beneficial physiological actions such as
improvements in insulin secretion and blood glucose
concentrations. Indeed, GLP-1Rs agonist mimic supra-
physiological blood concentrations of GLP-1 and have a
far longer half-life, varying between 1.5 hours and 5 days
depending on the agent [89]. Nonetheless, GLP-1Rs ago-
nists only exert their effects through an endocrine route,
while endogenous GLP-1 employs both endocrine and
neuronal routes, and therefore such high concentrations
may not be needed. In fact, changes in GLP-1 blood
concentrations after bariatric surgery suggest that a rise
within physiologically normal blood concentrations may
be sufficient to promote beneficial metabolic effects.
Several studies have shown that Roux-en-Y gastric by-
pass increases GLP-1 blood concentrations up to four-
fold 6 months to 1 year after the procedure [92, 93].
This increase in GLP-1 concentrations is associated with
improvements in dietary choices and intake, further ex-
cess weight loss, improved glycaemic control, and often
T2D resolution [92, 94]. Le Roux et al. [92] showed that
individuals who underwent Roux-en-Y gastric bypass
within 36 months had significantly higher GLP-1 blood
concentrations 30 minutes following a meal ingestion
(47.4 ± 11.4 pmol/L) compared to subjects with morbid
obesity (13.5 ± 6.9 pmol/L). Postprandial GLP-1 concen-
trations observed in subjects who underwent Roux-en-Y
gastric bypass were within physiologically normal GLP-1
concentration ranges, and therefore it is plausible that
promoting a similar increase in GLP-1 postprandial se-
cretion with dietary approaches would promote similar
beneficial actions on food intake, glycaemic control and
weight management over time.
Nutritional modulation of glucagon-like peptide-1
secretion
The nutrient composition of ingested food and meals
varies considerably between individuals and within the
same individual over the course of the day. In this re-
gard, macronutrient composition of the diet has been
shown to influence appetite and metabolic responses, in-
cluding glycaemia and insulinemia [95, 96]. One possible
mechanism to explain the differential effects of macro-
nutrients on these parameters is the modulation of GLP-
1 secretion by their catabolic by-products. As described
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macronutrients’ breakdown, including monosaccharides
[97–102], short-chain fatty acids (SCFAs) [103–109],
medium and long-chain fatty acids [110, 111] , as well as
amino acids and peptides [112–116], leading to GLP-1
secretion.
Nutrients and single-nutrient foods
Monosaccharides
Upon ingestion, digestible carbohydrates undergo enzym-
atic degradation and are absorbed in the form of glucose,
and to a lesser extent in the form of galactose and fruc-
tose. Glucose absorption by enterocytes as well as
glucose-mediated GLP-1 secretion from L-cells appear to
be mediated by the sodium glucose transporter-1 (SGLT-
1), a membrane transport protein expressed in the small
intestine [97–102]. Moriya and colleagues [98] investi-
gated the mechanisms underlying glucose-stimulated
GLP-1 secretion by administering glucose and Phloritzine,
a competitive inhibitor of SGLT-1, in the small intestine of
mice. While glucose administration alone acutely in-
creased circulating GLP-1, co-administration of glucose
and Phloritzine blocked first-phase glucose-induced GLP-
1 secretion [98]. Similarly, compared to controls, SGLT-1
knockout mice had decreased first-phase GLP-1 secretion
and developed glucose and galactose malabsorption [99].
This is explained by the fact that glucose binding to
SGLT-1 induces the closure of ATP-sensitive potassium
channels, leading to membrane depolarization and to a
rise in intracellular calcium concentrations [117]. Collect-
ively, this work outlines the importance of SGLT-1 in lu-
minal monosaccharide absorption, as well as glucose-
mediated GLP-1 secretion in the proximal small intestine.
The characterization of GLP-1’s secretion as being bi-
phasic led researchers to investigate the prolonged effect
the pharmacological inhibition of SGLT-1 in rodents and
humans [100–102]. While also confirming an inhibition of
first-phase GLP-1 secretion and an increase in luminal
glucose concentrations, Powell and al. [100] found an in-
crease in second-phase GLP-1 secretion and a decrease in
blood glucose excursions over a 6-hour postprandial
period in mice. These results were confirmed in two clin-
ical studies conducted in healthy adults, as well as in
adults with T2D [101, 102]. The increase in second-phase
GLP-1 secretion observed in these studies suggests that
SGLT-1 inhibition enhances other mechanisms promoting
GLP-1 secretion from the distal part of GI tract. As pro-
posed by the authors, possible explanations include an en-
hanced opportunity for interactions with L-cells as
carbohydrates move down the GI tract during digestion,
as well as an increased fermentation of undigested carbo-
hydrates in the colon which could raise the production of
SCFAs [100–102]. Concordant with the latter hypothesis,
Powell and al. [100] observed a decrease in the pH of thecaecum – which could indeed be an indicator of increased
bacterial fermentation – in SGLT-1 knockout mice as well
as mice that received a SGLT-1 inhibitor.
Non-digestible carbohydrates and short-chain fatty acids
In the colon, non-digestible carbohydrates undergo fer-
mentation, leading, depending on their type, to the pro-
duction of various amounts of SCFAs [118–121]. SCFAs
are carboxylic acids that contain fewer than 6 carbons,
the most abundant ones being acetate, butyrate and pro-
pionate [122]. In humans, SCFAs concentrations range
from ~130 mmol/L in the caecum to ~80 mmol/L in the
descending colon [122, 123]. Acetate appears to be the
most abundant SCFA in the colon, followed by propion-
ate and butyrate, with an overall colonic molar ratio of
50-60:15-20:10-20, respectively [122, 123].
Fermentable dietary fiber and their metabolites, the
SCFAs, seem to promote GLP-1 secretion from L-cells by
interacting with the free fatty acid receptors 2 and 3
(FFAR2, FFAR3) [103–109]. An in vitro study showed that
propionate was the most potent agonist of both FFAR2
and FFAR3, that acetate was more active and selective on
FFAR2, and that butyrate was more active on FFAR3 than
FFAR2 [105]. In colonic cell cultures, physiological con-
centrations of acetate, butyrate and propionate have been
shown to stimulate GLP-1 secretion [124]. The role played
by FFAR2 and FFAR3 in the SCFA-induced GLP-1 secre-
tion was confirmed by demonstrating the loss of postpran-
dial GLP-1 secretion in FFAR2 and FFAR3 knockout
intestinal cells [124]. Similar results were found in vivo,
where propionate-induced GLP-1 secretion was lost in
FFAR2 knockout rodents [125]. Additionally, Chambers
and colleagues [126] recently showed that acute targeted
delivery of propionate in the colon through an inulin-
propionate ester supplement acutely stimulated GLP-1 se-
cretion following a standard breakfast meal and reduced
energy intake at a buffet-style lunch in adults with over-
weight or obesity. Concordant with the acute effects of
GLP-1 on appetite sensations and food intake, daily deliv-
ery of propionate in the colon over 6 months also reduced
body weight, abdominal fat and hepatic lipid accumulation
as assessed with magnetic resonance imagery and spec-
troscopy [126].
The effects of diets rich in fermentable fiber on GLP-1
secretion have also been investigated in animal models
and humans [127, 128]. Indeed, the main way to increase
colonic SCFA concentrations in humans is through non-
digestible carbohydrate consumption. The results from six
experimental studies assessing the impact of fiber on
GLP-1 secretion in animal models and humans are sum-
marized in Table 1. Compared to a standard control diet,
the consumption of a diet enriched in fermentable fiber
for 50 days increased GLP-1 concentrations in the prox-
imal colon, which was associated with an increased
Table 1 Chronica effects of non-digestible carbohydrates on glucagon-like peptide-1 (GLP-1) secretion and associated outcomes





〉 Male Wistar rats Oligofructose
(10% of dietb)
↑ GLP-1 concentrations in the proximal and medial colon
↑ Proglucagon mRNA concentrations in the caecum and proximal colon
↓ Triglyceride blood and hepatic concentrations
↓ Food and energy intake







↑ Proglucagon mRNA concentrations in the proximal colon
↑ Pro-hormone convertase 1 mRNA concentrations in the proximal colon
↑ GLP-1 concentrations in the portal vein
↑ Glucose tolerance
↑ Insulin and C-peptide blood concentrations
↑ Pancreatic β-cell mass
↓ Food and energy intake
Cani 2005c
[131]
〉 Healthy men and women Oligofructose
(16 g/day)
↓ Energy intake over 24 hours
↑ Satiety
↓ Hunger
↓ Prospective food consumption
Cani 2006
[133]




↑ GLP-1 concentrations in the proximal colon
↑ GLP-1 concentrations in the portal vein
↑ Proglucagon mRNA concentrations in the proximal colon
↑ Blood and pancreatic insulin concentrations
↓ Fasting and postprandial blood glucose concentrations
Cani 2007
[134]
〉 Male Wistar rats Oligofructose
(10% of dietb)
↑ GLP-1 concentrations in the portal vein and proximal colon
↑ Proglucagon mRNA concentrations in the proximal colon
↑ L-cell number in the proximal colon
↑ Neurogenin-3 and Neuro-D mRNA concentrations in the proximal
colon
↓ Food and energy intake








↑ GLP-1 blood concentrations
↑ PYY blood concentrations
↓ Variation in blood glucose and insulin concentrations
↑ Proglucagon and PYY colonic mRNA concentrations
↑ Glucose tolerance in diabetic mice
GLP-1 Glucagon-like peptide-1, mRNA Messenger ribonucleic acid, PYY Peptide tyrosine-tyrosine
a 10 days - 1 year interventions
b weight : weight proportion
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mentable fiber also decreased food intake, weight gain, as
well as blood triglyceride concentrations and triglyceride
accumulation in the liver [129]. Similarly, while also in-
creasing GLP-1 blood concentrations and proglucagon ex-
pression in the colon, consumption of a diet rich in
resistant starch for 10 days increased peptide tyrosine-
tyrosine (PYY) blood concentrations and colonic expres-
sion in rats [130]. This result is not surprising as the anor-
ectic PYY is also synthesized and released from L-cells,
and its secretion could be stimulated by similar mecha-
nisms as that of GLP-1. In healthy humans, a crossover
pilot study showed that the daily supplementation with
16 g of fermentable fiber for a two-week period increased
postprandial satiety, and decreased hunger, prospective
food consumption as well as energy intake over 24 hours
following the intake of a standard breakfast meal [131]. As
GLP-1 blood concentrations were not assessed in this
study, it is not known whether these effects were mediated
by an increase in its secretion or through othermechanisms [131]. The effects of fermentable fiber in ro-
dent models of diabetes were comparable to those found
in healthy animals. Indeed, consumption of a diet enriched
with fermentable fiber for 4 to 6 weeks increased GLP-1
concentrations in the proximal colon and portal vein, as
well proglucagon expression in the proximal colon [132,
133]. In streptozotocin-treated diabetic rats, the fiber-
enriched diet also up-regulated pro-hormone convertase 1
expression in the proximal colon and increased pancreatic
β-cell mass which potentially mediated the improvement
in glucose tolerance and the observed increase in insulin
and C-peptide blood concentrations [132]. In mice with
high-fat diet-induced diabetes, these effects were dimin-
ished with the use of a GLP-1R antagonist and were com-
pletely lost in a GLP-1R knockout group of rats, therefore
confirming the importance of GLP-1 interaction with its
receptors for exerting its beneficial effects [133].
Overall, results from these studies suggest some path-
ways linking fermentable fiber to its positive effects on
food intake, body weight gain and blood glucose
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mentable fiber and SCFAs produced by their colonic fer-
mentation appear to increase GLP-1 synthesis by up-
regulating the expression of proglucagon [129, 132–134],
as well as that of pro-hormone convertase 1 [132], which,
as discussed above, is responsible for its cleavage [15].
Cani and colleagues [134] also found an increased prox-
imal colon’s L-cell number with fermentable fiber con-
sumption, which could be another possible explanation
for the increased GLP-1 synthesis and secretion. The in-
crease in L-cell number was also associated with an en-
hanced expression of transcription factors that are critical
for the differentiation of intestinal stem cells into enter-
oendocrine cells, namely neuregenin-3 and neuro-D [134].
Free fatty acids
The majority of dietary lipids are triglycerides, which are
composed of a glycerol molecule and three fatty acids
[135]. Upon ingestion, triglycerides undergo emulsifica-
tion by bile salts in the duodenum, hydrolysis by lipases,
and are absorbed by enterocytes in the form of glycerol
and free fatty acids [135].
Free fatty acids, such as unsaturated long-chain fatty
acids, are potent stimulators of GLP-1 release through in-
teractions with free fatty acid receptors 1 and 4 (FFAR1,
FFAR4) [110, 111]. Substrate binding to FFAR1 and FFAR4
activate phospholipase C, leading to inositol triphosphate
mediated calcium release from the endoplasmic reticulum
into the cytosol [136]. The secretion of GLP-1 has been
shown to be increased by unsaturated long-chain fatty
acids. The main outcomes of nine experimental studies
assessing the impact of lipid consumption on GLP-1 secre-
tion and blood concentrations are summarized in Table 2.
Thomsen and colleagues (1999, 2003) were the first ones to
assess GLP-1 responses following a meal containing olive
oil in healthy adults or adults with T2D [137, 138]. Com-
pared with a meal containing butter, which is high in satu-
rated fatty acids (SFAs), the ingestion of the olive oil
containing meal resulted in higher postprandial GLP-1
blood concentrations [137, 138]. However, no significant
acute difference in blood glucose, nor insulin blood concen-
trations was observed [137, 138]. In a subsequent study
conducted in rodents, the prolonged consumption of an
olive oil-enriched diet resulted in an increased GLP-1 secre-
tion, which coincided with a higher glucose-stimulated in-
sulin secretion, as well as an improved glucose tolerance at
the 36th day of the intervention [139]. Comparable results
were found in Streptozotocin-treated diabetic rats, where
the intake of a diet rich in monounsaturated fatty acids
(MUFAs) from olive oil for 50 days increased GLP-1 blood
concentrations, decreased weight gain and improved insu-
lin sensitivity [140]. In humans with abdominal obesity and
insulin resistance, Paniagua and colleagues [141] showed
that ingestion of a Mediterranean diet rich in olive oil for28 days resulted in significantly higher postprandial GLP-1
blood concentrations. Compared to a diet high in SFAs,
consumption of the Mediterranean diet also improved insu-
lin sensitivity, an effect which could have mediated the ob-
served decrease in insulin secretion as well as fasting and
postprandial blood glucose concentrations [141].
In addition to the beneficial effects of MUFAs, some
studies showed that the colonic administration of the
polyunsaturated α-linolenic acid acutely increased GLP-
1 and insulin blood concentrations, and decreased blood
glucose concentrations in healthy and diabetic rat
models [142]. Similarly, while also resulting in increased
GLP-1 blood concentrations, long-term administration
of α-linolenic acid has been shown to increase β-cell
proliferation in rodents [143]. As GLP-1 has been shown
to decrease apoptosis, as well as to increase neogenesis
of pancreatic β-cells, the authors hypothesized that the
increased β-cell proliferation was mediated by the in-
crease in GLP-1 concentrations induced by α-linolenic
acid ingestion [143]. A recent study showed that fish oil
and flax seed oil, which are a source of α-linolenic acid,
increased FFAR4 expression in rodents’ colon and de-
creased the expression of the pro-inflammatory tumour
necrosis factor α (TNFα) [144].
Taken together, these studies suggest that, with similar
energy contents, diets that are richer in MUFAs or
omega-3 polyunsaturated fatty acids (PUFAs) than in
SFAs, could increase GLP-1 secretion from L-cells,
which may be a mediator for the increase in insulin se-
cretion, insulin sensitivity, β-cell proliferation, as well as
the improved glucose tolerance observed in animal
models and in humans.
Peptides and amino acids
Dietary proteins are generally described as the most sati-
ating nutrient, an effect which may be partly mediated
by the stimulation of anorexigenic GI peptides secretion,
including that of GLP-1 [145–147]. Upon ingestion, pro-
teins are broken down by acid hydrolysis and proteases
to produce peptones, tripeptides, dipeptides and single
amino acids. Specifics mechanisms responsible for
protein-induced GLP-1 secretion are relatively poorly
understood, and the optimal profile of proteins’ break-
down products remains to be elucidated. Nonetheless,
two pathways by which products of protein breakdown
seem to stimulate GLP-1 secretion is through their bind-
ing to the calcium-sensing receptors (CaSR) and the
class C, group 6, subtype A GPCR (GPCR-C6A) which
are expressed on L-cells. CaSR binds to a variety of
amino acids including phenylalanine, tryptophan, aspara-
gine, arginine, glutamine and histidine, as well as to pep-
tones, tri- and dipeptides [112–116]. In vitro, their
binding to CaSR stimulated GLP-1 secretion, and this ef-
fect was abolished with the use of a CaSR inhibitor
Table 2 Acutea and chronicb effects of monounsaturated fatty acids (MUFAs) and omega-3 polyunsaturated fatty acids (PUFAs) on
glucagon-like peptide-1 (GLP-1) secretion and associated outcomes
Studies Experimental model Dietary intervention Main outcomes measured
Thomsen 1999
[137]
〉 Healthy men and women MUFAs from olive oila (80 g) ↑ GLP-1 blood concentrations




〉 Men and women with T2D MUFAs from olive oila (80 g) ↑ GLP-1 blood concentrations
↓ Triglyceride blood concentrations




〉 Male C57/B6 rats α-linolenic acid (0.1 μmol)a ↑ GLP-1 blood concentrations
↑ Insulin blood concentrations
Prieto 2005
[139]
〉 Wistar rats MUFAs from olive oilb,c ↑ GLP-1 blood concentrations











〉 Male C57BL/6 J mice
〉 Diabetic male NSY mice
〉 C3H/He mice
α-linolenic acid (0.3 μmol)a ↑ GLP-1 blood concentrations
↑ Insulin blood concentrations
↓ Blood glucose concentrations
Paniagua 2007
[141]
〉 Insulin resistant men and
women
MUFAs from an olive-oil containing
Mediterranean diet (23% of total
energy intake)b
↑ Postprandial GLP-1 concentrations
↑ Insulin sensitivity
↓ Postprandial insulin secretion




〉 Male Wistar rats α-linolenic acid (3 μmol)a,b ↑ GLP-1 blood concentrations
↑ pancreatic β-cell number and mass
Cheshmehkani 2015
[144]
〉 Male Sprague-Dawley rats Fish or flaxseed oilb,d
(10% of diet)
↑ FFAR4 expression in the colon
↓ TNFα blood concentrations
FFAR4: Free fatty acid receptor 4; GLP-1: Glucagon-like peptide-1; MUFAs: Monounsaturated fatty acids; SCFAs: Short-chain fatty acids; TNFα: Tumour necrosis
factor α
a Acute effect (5 minutes post-consumption)
b Chronic effect (28 to 50 days of consumption)
c Specific MUFA content not known
d weight : weight proportion
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GPCR-C6A binds to the basic amino acids arginine, ly-
sine and ornithine. The stimulatory effect of these amino
acids on GLP-1 secretion was abolished in GPCR-C6A
knockout intestinal cells [148].
Mixed-nutrient foods
In contrast with single nutrients and single-nutrient
foods (e.g. oil), more complex foods containing a mix of
nutrients are more representative of what humans con-
sume and could allow targeting a combination of enter-
oendocrine pathways that would synergistically enhance
GLP-1 secretion. In regards to T2D management, clin-
ical guidelines recommend carbohydrate intake from
high-fiber foods such as vegetables, fruit, legumes and
whole grains, while limiting SFAs intake and promoting
that of MUFAs and omega-3 PUFAs [149, 150], all of
which have been associated to different extents with an
increased GLP-1 secretion.
Some experimental studies conducted with healthy in-
dividuals have examined the effects of several specificfoods on glycemic response, subjective appetite sensa-
tions as well as energy intake at a subsequent meal
[151–168]. The main findings of these studies are sum-
marized in Table 3. Several researchers have investigated
the effects of high-fiber grain products, which could en-
hance GLP-1 secretion by binding to SGLT-1, FFAR2
and FFAR3. In this regard, two recent studies compared
appetite responses after isoenergetic breakfast meals
containing ready-to-eat breakfast cereals (low-fiber) or
oatmeal (high-fiber) among healthy young adults [151,
152]. Compared to ready-to-eat breakfast cereals, oat-
meal (66.8 g) increased fullness, and reduced hunger, de-
sire to eat, as well as subjective prospective food intake
[151, 152]. Furthermore, oatmeal decreased energy in-
take at the following meal [152]. Likewise, in adults with
insulin resistance, daily consumption of a high wheat-
fiber breakfast cereal (test group, 24 g/day of fiber from
the cereal) for one year, significantly increased colonic
SCFAs production, as well as GLP-1 blood concentra-
tions compared to low-fiber breakfast cereals (control
group, 0.5 g/day of fiber from the cereal) [165]. More
Table 3 Summary of experimental studies assessing the effects of mixed-nutrient foods on glucagon-like peptide-1 (GLP-1) secretion
and associated outcomes
Studies Subjects Dietary intervention Main outcomes measured
N Characteristics Food Duration
Rebello 2013 [151] 48 〉 Healthya Oatmealb (66.8 g) 4 h ↑ Fullness
↓ Hunger
↓ Desire to eat
↓ Prospective food consumption
Rebello 2016 [152] 48 〉 Healthy Oatmealb (66.8 g) 4 h ↑ Fullness
↓ Hunger
↓ Desire to eat
↓ Prospective food consumption
↓ Energy intake at the next meal
Freeland 2010 [165] 28 〉 Hyperinsulinemia High-fiber cereal
(24 g/day)
1 year ↑ Acetate and butyrate blood concentrations
↑ GLP-1 blood concentrations
Nilsson 2015 [166] 20 〉 Healthy Barley kernel-based
breadc
(100 g of available starch
per day)
3 days ↑ PYY postprandial blood concentrations
↑ GLP-1 fasting blood concentrations
↑ Fasting and postprandial breath hydrogen
concentrations
↑ Total SCFAs and acetate fasting blood
concentrations
↓ Blood glucose postprandial concentrations
↓ Insulin postprandial blood concentrations
Jenkins 2006 [156] 15 〉 Healthy Raw almondsb (60.0 g) 4 h ↓ Blood glucose postprandial concentrations
↓ Insulin postprandial blood concentrations
↓ Oxydative damage to proteins measured in blood
serum
Josse 2007 [167] 9 〉 Healthy Raw almondsc
(30, 60 and 90 g)
4 h ↓ Blood glucose postprandial concentrationsd
Jenkins 2008 [157] 27 〉 Hyperlipidemia Raw almonds-
(37.0 and 73.0 g)
1 month ↓ 24-hour insulin secretion
Mori 2011 [159] 14 〉 Impaired glucose
tolerance
Raw almondsc (42.5 g) 8 h ↓ Blood glucose concentrations
↑ Insulin blood concentrations
↓ Non esterified fatty acid blood concentrations after a
second meal
↑ Fullness
Kendall 2011 [153] 10 〉 Healthy Pistachiosb
(28.0, 56.0 and 84.0 g)
2 h ↓ Blood glucose concentrationsd
Kendall 2014 [154] 20 〉 Metabolic syndrome Pistachiosc (85.0 g) 3 h ↑ GLP-1 postprandial blood concentrations
↑ Glucose-insulinotropic peptide postprandial blood
concentrations
↓ Blood glucose postprandial concentrations
↑ Insulin postprandial blood concentrations




8 h ↓ Blood glucose concentrations after second standard
isocaloric meal (b)
↑ Insulin postprandial blood concentrations (a,b)
↓ Non esterified fatty acid blood concentrations after
second meal (b)
↑ PYY postprandial blood concentrations (b)
↓ Desire to eat following the second meal (a,b)
Parham 2014 [155] 48 〉 Type 2 diabetes Pistachiod (50.0 g per
day)
12 weeks ↓ Fasting blood glucose concentrations
↓ Percentage of glycated blood haemoglobin
↓ Systolic blood pressure
↓ Body mass index
↓ C-reactive protein blood concentrations
Ratliff 2010 [160] 21 〉 Healthy men Whole eggb (3) 24 h ↓ Blood glucose postprandial concentrations
↓ Ghrelin postprandial blood concentrations
↓ Insulin postprandial blood concentrations
↓ Hunger
↑ Satisfaction
↓ Energy intake at lunch and over 24 hours
31 〉 Healthy Whole eggsb (2) 4 h ↑ Fullness
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Table 3 Summary of experimental studies assessing the effects of mixed-nutrient foods on glucagon-like peptide-1 (GLP-1) secretion
and associated outcomes (Continued)
Pombo-Rodrigues
2011 [162]
↓ Desire to eat
↓ Prospective food consumption
Vander Wal 2005
[161]
30 〉 Overweight women Whole eggsb (2) 36 h ↑ Satiety




28 〉 Healthy children and
adolescents
Eggsb 3 h ↑ PYY postprandial blood concentrations
Wien 2013 [164] 26 〉 Overweight Fresh avocadob
(50.0 to 90.0 g)
3 h ↓ Insulin postprandial blood concentrations
↓ Desire to eat
↑ Satisfaction
GLP-1 Glucagon-like peptide-1, PYY Peptide tyrosine-tyrosine, SCFAs Short-chain fatty acids
a Unless otherwise mentioned, study samples include adults of both sexes
b Isocaloric test and control meals, however, not marched for macronutrient contents
c Test and control meals matched for carbohydrate content only
d In a dose-dependent matter
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and butyrate plasma concentrations were already signifi-
cantly higher in the test group [165]. Along the same
lines, Nilsson and colleagues [166] showed that con-
sumption of high-fiber barley kernel-based bread for
3 days was associated with increased fasting GLP-1
blood concentrations, as well as increased postprandial
PYY blood concentrations in healthy adults. These
changes in GI peptides concentrations were associated
with improved insulin sensitivity and decreased post-
prandial blood glucose concentrations in healthy individ-
uals [166]. The fact that the authors found an increase
in breath hydrogen and SCFAs blood concentrations,
suggests that the positive effects of the barley kernel-
based bread were mediated by an increased SCFAs pro-
duction triggered by the colonic of dietary fiber [166].
The addition of foods with a high protein, MUFAs and
fiber content, such as almonds (30.0 to 90.0 g) or pista-
chios (28.0 to 85.0 g) to a high-carbohydrate meal has
also been shown to improve postprandial glycemic re-
sponses in a dose-dependent manner [153–159, 167].
Jenkins and colleagues [156] also found a decrease in in-
sulin secretion in healthy adults and in adults with
hyperlipidemia following acute and prolonged almond
consumption. Similarly, daily intake of 50.0 g of pista-
chios for 12 weeks decreased C-reactive protein blood
concentrations, systolic blood pressure, and body mass
index in adults with T2D [155]. In women with obesity,
consumption of peanuts (42.5 g) or peanut butter
(42.5 g) as part of a standard breakfast meal increased
postprandial insulin blood concentrations and decreased
desire to eat following a standard lunch meal [166].
Additionally, peanut butter significantly increased post-
prandial PYY blood concentrations and decreased post-
prandial blood glucose concentrations following the
standard lunch meal [166]. Since GLP-1 and PYY are co-
released from L-cells [12], it is plausible that peanut but-
ter may also promote postprandial GLP-1 secretion.Only three of these studies assessed GLP-1 blood con-
centrations [154, 159, 168]. Mori et al. [159] found no
significant differences in GLP-1 blood concentrations
following the addition of 42.5 g of almonds to a
carbohydrate-containing meal, which could be due to
the small sample size of the study. Indeed, with a larger
sample size, Kendall et al. [154] found higher GLP-1 and
glucose insulinotropic peptide blood concentrations fol-
lowing the addition of 85.0 g of pistachios to a
carbohydrate-containing meal in adults with metabolic
syndrome. As Reis et al. [168] showed no statistically
significant difference in GLP-1 blood concentrations
with the addition of 42.5 g of peanuts or peanut butter
to a carbohydrate-containing meal, it is also possible that
higher quantities of nuts are necessary to induce a suffi-
cient rise in GI hormone secretion.
Consumption of eggs (2 to 3), which are high in pro-
tein and also contain MUFAs, for breakfast or lunch, has
been shown to improve subjective postprandial appetite
sensations [160–163]. Furthermore, when compared to a
bagel breakfast, consumption of a breakfast containing
eggs (3) in adult men was associated with a lower post-
prandial blood glucose concentrations, decreased hun-
ger, and reduced energy intake in the next 24 hours
[160]. Men also reported higher subjective satisfaction
after eating eggs [160]. While GLP-1 blood concentra-
tions were not measured in these studies, Li and al.
[163] found a significant increase in postprandial blood
concentrations of PYY in adolescents following ingestion
of an egg-containing breakfast compared to an isocaloric
bagel breakfast. One study also showed that adding avo-
cado (50 to 90 g), which is high in fiber and MUFAs, to
a high-carbohydrate isocaloric meal improved subjective
satiety sensation and satisfaction [164].
Discussion and Conclusion
In light of this literature review, it is evident that ma-
nipulating the composition of the diet in order to
Bodnaruc et al. Nutrition & Metabolism  (2016) 13:92 Page 11 of 16promote GLP-1 secretion represents a promising life-
style strategy for obesity and T2D management. The
therapeutic potential of GLP-1 has already been estab-
lished as several pharmaceutical agents promoting its
effects are successfully used for blood glucose manage-
ment in individuals with T2D, and for body weight man-
agement in individuals with obesity [87, 89]. In
comparison with the use of GLP-1Rs agonists and DPP-
IV inhibitors, targeting endogenous pathways through
dietary modifications has the added benefits of poten-
tially stimulating the release of other anorexigenic gut
peptides (e.g. PYY), promoting beneficial changes in sev-
eral markers of cardiometabolic health such as helping
normalize blood lipid profile and blood pressure, as well
as avoiding side effects associated with medication. Fur-
thermore, as DPP-IV pharmacological action depends
on the bioavailability of endogenous GLP-1 into the
blood-stream, combining the use of this drug type with
a diet promoting GLP-1 secretion could promote DPP-
IV inhibitors’ action and potentially allow the use of
lower doses. Therefore, it would be worthwhile to inves-
tigate the relationship between diet composition and
DPP-IV inhibitors’ efficacy in future studies.
When summarizing existing studies on the modulation
of endogenous GLP-1 secretion from enteroendocrine
L-cells by single nutrients and their by-products (e.g.
non digestible carbohydrates and SCFAs), single-
nutrient foods (e.g. olive oil, fish oil) as well as mixed-
nutrient foods, it appears that the nutritional modulation
of GLP-1 secretion involves several GPCRs expressed on
L-cells. Furthermore, specific mechanisms for the in-
crease in GLP-1 synthesis and secretion in L-cells in-
clude the up-regulation of proglucagon expression [129,
132–134], as well as that of post-transcriptional factors
(e.g. pro-hormone convertase 1) [132]. The synthesis
and secretion of GLP-1 may also be enhanced by pro-
moting the differentiation of intestinal stem cells into L-
cells [134].
In comparison with single nutrients, mixed-nutrient
foods theoretically constitute a more promising and
practical treatment option as they can allow targeting
several enteroendocrine pathways. The main limitation
of existing studies assessing the effects of specific foods
is that it is impossible to distinguish the specific impact
of macronutrient types (e.g. MUFAs versus SFAs) from
the impact of the amount of the intake per se because
none of the experimental meals were matched for
macronutrient content. Furthermore, several studies
[154, 156, 161, 167, 168] did not use isocaloric test and
control meals. In these studies, the test meal was con-
tained more calories which leads to question whether
the observed effects is to be attributed to the tested
foods or the energy content of the meal. These limita-
tions call for more rigorous experimental designs toconfirm the effects of these foods on GLP-1’s and other
gut hormone’s secretion. Future studies should also aim
to gain a better understanding of dose-specific effects of
single nutrients, mixed nutrients, specific foods and food
combinations in humans. There is also a need to com-
pare the effects of food ingestion on GLP-1 secretion in
healthy adults versus adults with metabolic disturbances
such as metabolic syndrome, impaired glucose tolerance,
and T2D. Well-designed randomised control trials
should be planned to evaluate the impact of foods pro-
moting GLP-1 secretion on the progression from im-
paired glucose tolerance to frank T2D. Lastly, efforts
should be made to identify ranges of postprandial GLP-1
concentrations that are associated with beneficial meta-
bolic effects acutely and in the long-term. Such know-
ledge advances could help individuals modify their
dietary habits in a way that obesity and T2D could be
better managed and maybe prevented.
Abbreviations
AgRP: Agouti-related peptide; ARC: Arcuate nucleus; CART: Cocaine and
amphetamine-regulated transcript; CaSR: Calcium-sensing receptor;
DMN: Dorso-medial nucleus; DPP-IV: Dipeptidyl-peptidase IV; FFAR1-4: Free
fatty acid receptor 1-4; GI: Gastrointestinal; GLP-1: Glucagon-like peptide-1;
GLP-1R(s): Glucagon-like peptide-1 receptor(s); GPCR(s): G-protein coupled
receptor(s); GPCR-C6A: Class C group 6, subtype A G-protein coupled
receptor; mRNA: Messenger ribonucleic acid; MUFA(s): Monounsaturated
fatty acid(s); NPY: Neuropeptide Y; NTS: Nucleus tractus solitarius; POMC: Pro-
opiomelanocortine; PUFA(s): Polyunsaturated fatty acid(s);
PVN: Paraventricular nucleus; PYY: Peptide tyrosine-tyrosine; SFA(s): Saturated
fatty acid(s); SGLT-1: Sodium glucose transporter-1; T2D: Type 2 diabetes;




This review was supported by a pilot study grant from the Montfort Hospital
Research Institute to IG. AMB is supported by master scholarships from the
Canadian Institute of Health Research and from the Montfort Hospital
Research Institute. RB is supported by a doctoral scholarship from Fonds de
Recherche en Santé du Québec.
Availability of data and material
Not applicable as no datasets were generated or analysed for this review
article.
Authors’ contribution
AMB, DP and IG formulated the aim of this review. AMB conducted the
bibliographical search, critically reviewed articles included in this paper and
took primary responsibility in its redaction. DP, RB and IG participated in the
critical review of selected articles and revised this paper for important
intellectual content. All co-authors read and approved the final version of
this manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Bodnaruc et al. Nutrition & Metabolism  (2016) 13:92 Page 12 of 16Author details
1School of Human Kinetics, Faculty of Health Sciences, University of Ottawa,
35, University Private, Room 050F, K1N 6N5 Ottawa, ON, Canada. 2Institut de
Recherche de l’Hôpital Montfort, Institut du savoir, 745 Montreal Road, Room
202, K1K 0T2 Ottawa, ON, Canada. 3School of Nutrition Sciences, Faculty of
Health Sciences, University of Ottawa, 35 University Private, Room 050F, K1N
6N5 Ottawa, ON, Canada. 4School of Nutrition Sciences, Faculty of Health
Sciences, University of Ottawa, 25 University Private, Room 116, K1N 6N5
Ottawa, ON, Canada.
Received: 19 October 2016 Accepted: 30 November 2016
References
1. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S,
Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes
mellitus: Meta-analysis of randomized trials. Am Heart J. 2006;152:27–38.
2. Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, Pouwer F. Type
2 diabetes mellitus as a risk factor for the onset of depression: a systematic
review and meta-analysis. Diabetologia. 2010;53:2480–6.
3. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and
quality of life: a population study. Diabetes Care. 2004;27:1066–70.
4. Anderson JW, Kendall CWC, Jenkins DJA. Importance of weight
management in Type 2 diabetes: review with meta-analysis of clinical
studies. J Am Coll Nutr. 2003;22:331–9.
5. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J,
Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality
in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet.
2009;373:1083–96.
6. Kelly T, Yang W, Chen C-S, Reynolds K, He J. Global burden of obesity in
2005 and projections to 2030. Int J Obes (Lond). 2008;32:1431–7.
7. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes:
Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;
27:1047–53.
8. Schoeller D a. The energy balance equation: looking back and looking
forward are two very different views. Nutr Rev. 2009;67:249–54.
9. Doucet É, Cameron J. Appetite control after weight loss: what is the role of
bloodborne peptides? Appl Physiol Nutr Metab. 2007;32:523–32.
10. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.
11. Reimann F, Tolhurst G, Gribble FM. G-protein-coupled receptors in intestinal
chemosensation. Cell Metab. 2012;15:421–31.
12. Gunawardene AR, Corfe BM, Staton CA. Classification and functions of
enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol.
2011;92:219–31.
13. Han VK, Hynes MA, Jin C, Towle AC, Lauder JM, Lund PK. Cellular
localization of proglucagon/glucagon-like peptide I messenger RNAs in rat
brain. J Neurosci Res. 1986;16:97–107.
14. Larsen P, Tang-Christensen M, Holst J, Ørskov C. Distribution of glucagon-
like peptide-1 and other preproglucagon-derived peptides in the rat
hypothalamus and brainstem. Neuroscience. 1997;77:257–70.
15. Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the
tissue-specific processing of proglucagon. Mol Endocrinol. 1996;10:342–55.
16. Conlon J. Proglucagon-derived peptides: nomenclature, biosynthetic
relationships and physiological roles. Diabetologia. 1988;31:563–6.
17. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF.
Preproglucagon gene expression in pancreas and intestine diversifies at the
level of post-translational processing. J Biol Chem. 1986;261:11880–9.
18. Novak U, Wilks A, Buell G, McEwen S. Identical mRNA for preproglucagon in
pancreas and gut. Eur J Biochem. 1987;164:553–8.
19. Tucker JD, Dhanvantari S, Brubaker PL. Proglucagon processing in islet and
intestinal cell lines. Regul Pept. 1996;62:29–35.
20. Nauck MA, Siemsglüss J, Orskov C, Holst JJ. Release of glucagon-like peptide
1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in
response to oral glucose after upper and lower intestinal resections. Z
Gastroenterol. 1996;34:159–66.
21. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by
human plasma in vitro yields an N-terminally truncated peptide that is a major
endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80:952–7.
22. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1
undergoes differential tissue-specific metabolism in the anesthetized pig.
Am J Physiol Endocrinol Metab. 1996;271:E458–464.23. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-
36)amide is transformed to glucagon-like peptide-1-(9-36)amide by
dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine
intestine. Endocrinology. 1999;140:5356–63.
24. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W.
Incretin effects of increasing glucose loads in man calculated from venous
insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492–8.
25. Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones
glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with
insulin secretion in normal man throughout the day. Scand J Gastroenterol.
1996;31:665–70.
26. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom
SR. Glucagon-like peptide 1 has a physiological role in the control of
postprandial glucose in humans: studies with the antagonist exendin 9-39.
Diabetes. 1999;48:86–93.
27. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like
peptide-1 is a physiological incretin in rat. J Clin Invest. 1995;95:417–21.
28. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like
peptide I stimulates insulin gene expression and increases cyclic AMP levels
in a rat islet cell line. Proc Natl Acad Sci U S A. 1987;84:3434–8.
29. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in
Type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52.
30. Madsbad S, Kehlet H, Hilsted J, Tronier B. Discrepancy between plasma C-
peptide and insulin response to oral and intravenous glucose. Diabetes.
1983;32:436–8.
31. Holst JJ. Role of incretin hormones in the regulation of insulin secretion in
diabetic and nondiabetic humans. AJP Endocrinol Metab. 2004;287:E199–206.
32. Kaneko K, Shirotani T, Araki E, Matsumoto K, Taguchi T, Motoshima H,
Yoshizato K, Kishikawa H, Shichiri M. Insulin inhibits glucagon secretion by the
activation of PI3-kinase in In-R1-G9 cells. Diabetes Res Clin Pract.
1999;44:83–92.
33. Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets
is a physiologic glucagon release inhibitor. J Clin Invest. 1984;74:2296–9.
34. De Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not
glucose-dependent insulinotropic peptide, inhibits glucagon secretion via
somatostatin (receptor subtype 2) in the perfused rat pancreas.
Diabetologia. 2008;51:2263–70.
35. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, Polonsky KS.
Role of apoptosis in failure of beta-cell mass compensation for insulin
resistance and beta-cell defects in the male Zucker diabetic fatty rat.
Diabetes. 1998;47:358–64.
36. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like
peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem.
2003;278:471–8.
37. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R.
Glucagon-Like Peptide-1 Promotes Islet cell growth and inhibits apoptosis
in Zucker diabetic Rats. Endocrinology. 2013;143:4397–408.
38. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-Like Peptide-1 induces cell
proliferation and Pancreatic-Duodenum Homeobox-1 expression and
increases endocrine cell mass in the pancreas of old, Glucose-Intolerant
Rats. Endocrinology. 2013;141:4600–5.
39. Rui L. Brain regulation of energy balance and body weight. Rev Endocr
Metab Disord. 2013;14:387–407.
40. Morton GJ, Meek TH, Schwartz MW. Neurobiology of food intake in health
and disease. Nat Rev Neurosci. 2014;15:367–78.
41. Alvarez E, Roncero I, Chowen JA, Thorens B, Blázquez E. Expression of the
glucagon-like peptide-1 receptor gene in rat brain. J Neurochem. 1996;66:920–7.
42. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and
glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous
system. J Comp Neurol. 1999;403:261–80.
43. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS,
Woods SC, Seeley RJ, Herman JP, D’Alessio DA. Glucagon-like peptide-1
(GLP-1) receptors expressed on nerve terminals in the portal vein mediate
the effects of endogenous GLP-1 on glucose tolerance in rats.
Endocrinology. 2007;148:4965–73.
44. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 Binding
sites in the Rat brain: evidence that Exendin-4 is a Ligand of Brain GLP-1
Binding Sites. Eur J Neurosci. 1995;7:2294–300.
45. Orskov C, Poulsen SS, Møller M, Holst JJ. Glucagon-like peptide I receptors
in the subfornical organ and the area postrema are accessible to circulating
glucagon-like peptide I. Diabetes. 1996;45:832–5.
Bodnaruc et al. Nutrition & Metabolism  (2016) 13:92 Page 13 of 1646. Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS,
Hansen G, Grove KL, Pyke C, Raun K, Schäffer L, Tang-Christensen M, Verma S,
Witgen BM, Vrang N, Bjerre KL. The arcuate nucleus mediates GLP-1 receptor
agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4473–88.
47. Yang Y, Moghadam AA, Cordner ZA, Liang N-C, Moran TH. Long term exendin-4
treatment reduces food intake and body weight and alters expression of brain
homeostatic and reward markers. Endocrinology. 2014;155:3473–83.
48. Dockray GJ. Enteroendocrine cell signalling via the vagus nerve. Curr Opin
Pharmacol. 2013;13:954–8.
49. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S,
Kigoshi T, Nakayama K, Uchida K. Receptor gene expression of glucagon-like
peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat
nodose ganglion cells. Auton Neurosci. 2004;110:36–43.
50. Rüttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal
hepatic portal and intraperitoneal infusions of glucagon-like peptide-1
reduce spontaneous meal size in the rat via different mechanisms.
Endocrinology. 2009;150:1174–81.
51. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JRC, Ghatei MA,
Bloom SR. The inhibitory effects of peripheral administration of peptide YY(3-
36) and glucagon-like peptide-1 on food intake are attenuated by ablation of
the vagal-brainstem-hypothalamic pathway. Brain Res. 2005;1044:127–31.
52. Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA,
Maestre O, Gómez R, Muñoz RM, Eng J, Blázquez E. Peripheral versus central
effects of glucagon-like peptide-1 receptor agonists on satiety and body
weight loss in Zucker obese rats. Metabolism. 2000;49:709–17.
53. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and
peptide YY(3-36) synergistically reduce food intake through different
mechanisms in mice. Endocrinology. 2005;146:3748–56.
54. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of glucagon-like
peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in
rats. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1695–706.
55. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan
JM. Exendin-4 decelerates food intake, weight gain, and fat deposition in
Zucker rats. Endocrinology. 2000;141:1936–41.
56. Williams KE, Washington MC, Johnson-Rouse T, Johnson RE, Freeman C,
Reed C, Heath J, Sayegh AI. Exogenous glucagon-like peptide-1 acts in sites
supplied by the cranial mesenteric artery to reduce meal size and prolong
the intermeal interval in rats. Appetite. 2015;96:254–9.
57. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety
and suppresses energy intake in humans. J Clin Invest. 1998;101:515–20.
58. Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM. Glucagon-like
peptide 1 increases the period of postprandial satiety and slows gastric
emptying in obese men. Am J Clin Nutr. 1998;68:525–30.
59. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S,
Hellström PM. Energy intake and appetite are suppressed by glucagon-like
peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord.
1999;23:304–11.
60. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C.
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients
with diabetes mellitus type 2. Am J Physiol. 1999;276(5 Pt 2):R1541–4.
61. Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A. The effect of physiological levels
of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate
metabolism in obesity. Int J Obes Relat Metab Disord. 2001;25:781–92.
62. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of
glucagon-like peptide 1 lowers plasma glucose and reduces appetite in
type 2 diabetic patients. Diabetes Care. 1999;22:1137–43.
63. Berthoud H-R, Lenard NR, Shin AC. Food reward, hyperphagia, and obesity.
Am J Physiol Regul Integr Comp Physiol. 2011;300:R1266–77.
64. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Baler R. Food and drug reward:
overlapping circuits in human obesity and addiction. Curr Top Behav
Neurosci. 2012;11:1–24.
65. Van Bloemendaal L, Veltman DJ, Ten Kulve JS, Groot PFC, Ruhé HG, Barkhof
F, Sloan JH, Diamant M, Ijzerman RG. Brain reward-system activation in
response to anticipation and consumption of palatable food is altered by
glucagon-like peptide-1 receptor activation in humans. Diabetes Obes
Metab. 2015;17:878–86.
66. Stice E, Spoor S, Ng J, Zald DH. Relation of obesity to consummatory and
anticipatory food reward. Physiol Behav. 2009;97:551–60.
67. Stice E, Spoor S, Bohon C, Veldhuizen MG, Small DM. Relation of reward
from food intake and anticipated food intake to obesity: a functional
magnetic resonance imaging study. J Abnorm Psychol. 2008;117:924–35.68. Small DM, Jones-Gotman M, Dagher A. Feeding-induced dopamine release
in dorsal striatum correlates with meal pleasantness ratings in healthy
human volunteers. Neuroimage. 2003;19:1709–15.
69. Van Bloemendaal L, Veltman DJ, ten Kulve JS, Drent ML, Barkhof F, Diamant
M, IJzerman RG. Emotional eating is associated with increased brain
responses to food-cues and reduced sensitivity to GLP-1 receptor activation.
Obesity. 2015;23:2075–82.
70. Van Bloemendaal L, IJzerman RG, ten Kulve JS, Barkhof F, Konrad RJ, Drent ML,
Veltman DJ, Diamant M. GLP-1 Receptor activation modulates appetite- and
reward-related brain areas in humans. Diabetes. 2014;63:4186–96.
71. Dossat AM, Lilly N, Kay K, Williams DL. Glucagon-like peptide 1 receptors in
nucleus accumbens affect food intake. J Neurosci. 2011;31:14453–7.
72. Alhadeff AL, Grill HJ. Hindbrain nucleus tractus solitarius glucagon-like
peptide-1 receptor signaling reduces appetitive and motivational aspects of
feeding. Am J Physiol Regul Integr Comp Physiol. 2014;307:R465–70.
73. Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue,
exendin-4, attenuates the rewarding properties of psychostimulant drugs in
mice. PLoS One. 2013;8, e69010.
74. Ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Deacon CF, Holst
JJ, Konrad RJ, Sloan JH, Drent ML, Diamant M, IJzerman RG. Endogenous
GLP-1 mediates postprandial reductions in activation in central reward and
satiety areas in patients with type 2 diabetes. Diabetologia. 2015.
75. Mietlicki-Baase EG, Ortinski PI, Rupprecht LE, Olivos DR, Alhadeff AL, Pierce
RC, Hayes MR. The food intake-suppressive effects of glucagon-like peptide-
1 receptor signaling in the ventral tegmental area are mediated by AMPA/
kainate receptors. Am J Physiol Endocrinol Metab. 2013;305:E1367–74.
76. Wang X-F, Liu J-J, Xia J, Liu J, Mirabella V, Pang Correspondence ZP.
Endogenous Glucagon-like Peptide-1 Suppresses High-Fat Food Intake by
Reducing Synaptic Drive onto Mesolimbic Dopamine Neurons. Cell Reports.
2015;12:726–33.
77. Anderberg RH, Anefors C, Bergquist F, Nissbrandt H, Skibicka KP. Dopamine
signaling in the amygdala, increased by food ingestion and GLP-1, regulates
feeding behavior. Physiol Behav. 2014;136:135–44.
78. Fukase N, Igarashi M, Takahashi H, Manaka H, Yamatani K, Daimon M, Tominaga
M, Sasaki H. Hypersecretion of Truncated Glucagon-like Peptide-1 and Gastric
Inhibitory Polypeptide in Obese Patients. Diabet Med. 1993;10:44–9.
79. Fukase N, Manaka H, Sugiyama K, Takahashi H, Igarashi M, Daimon M,
Yamatani K, Tominaga M, Sasaki H. Response of truncated glucagon-like
peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-
insulin dependent diabetes mellitus. Acta Diabetol. 1995;32:165–9.
80. Ahren B, Larsson H, Holst J. Reduced gastric inhibitory polypeptide but
normal glucagon-like peptide 1 response to oral glucose in
postmenopausal women with impaired glucose tolerance. Eur J Endocrinol.
1997;137:127–31.
81. Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, Luciani
A, Salerni B, Mittenperger F, Nodari S, Gnudi A, Zandomeneghi R. Glucagon-
like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV)
activity in morbidly obese patients undergoing biliopancreatic diversion.
Horm Metab Res. 2004;36:111–5.
82. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of
glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab.
2001;86:3853–60.
83. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen
BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1
in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717–23.
84. Gutzwiller J-P, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C.
Glucagon-like peptide-1 promotes satiety and reduces food intake in
patients with diabetes mellitus type 2. Am J Physiol Regul Integr Comp
Physiol. 1999;276:R1541–1544.
85. Aulinger BA, Vahl TP, Wilson-Pérez HE, Prigeon RL, D’Alessio DA. β-Cell
Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to
Insulin Sensitivity. J Clin Endocrinol Metab. 2015;100:2489–96.
86. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not
of synthetic human gastric inhibitory polypeptide in patients with type-2
diabetes mellitus. J Clin Invest. 1993;91:301–7.
87. Enriori PJ, Evans AE, Sinnayah P, Cowley MA. Leptin resistance and obesity.
Obesity (Silver Spring). 2006;14 Suppl 5:254S–8S.
88. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet. 2006;368:1696–705.
Bodnaruc et al. Nutrition & Metabolism  (2016) 13:92 Page 14 of 1689. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists:
efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283.
90. U.S. Food and Drug Administration. FDA approves weight-management drug
Saxenda. 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm427913.htm.
91. Cefalu WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I,
Rosenstock J, Riddle MC. Beyond metformin: safety considerations in the
decision-making process for selecting a second medication for type 2
diabetes management: reflections from a diabetes care editors’ expert
forum. Diabetes Care. 2014;37:2647–59.
92. Le Roux CW, Aylwin SJB, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey
S, Ghatei MA, Patel AG, Bloom SR. Gut hormone profiles following bariatric
surgery favor an anorectic state, facilitate weight loss, and improve
metabolic parameters. Ann Surg. 2006;243:108–14.
93. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJB. Progressive
rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut
adaptation and explains altered satiety. Br J Surg. 2006;93:210–5.
94. Le Roux CW, Bueter M, Theis N, Werling M, Ashrafian H, Löwenstein C,
Athanasiou T, Bloom SR, Spector AC, Olbers T, Lutz TA. Gastric bypass
reduces fat intake and preference. Am J Physiol Regul Integr Comp Physiol.
2011;301:R1057–66.
95. Simpson RW, McDonald J, Wahlqvist ML, Atley L, Outch K. Macronutrients
have different metabolic effects in nondiabetics and diabetics. Am J Clin
Nutr. 1985;42:449–53.
96. Coulston AM, Hollenbeck CB, Liu GC, Williams RA, Starich GH, Mazzaferri EL,
Reaven GM. Effect of source of dietary carbohydrate on plasma glucose,
insulin, and gastric inhibitory polypeptide responses to test meals in
subjects with noninsulin-dependent diabetes mellitus. Am J Clin Nutr.
1984;40:965–70.
97. Dashty M. A quick look at biochemistry: carbohydrate metabolism. Clin
Biochem. 2013;46:1339–52.
98. Moriya R, Shirakura T, Ito J, Mashiko S, Seo T. Activation of sodium-glucose
cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion
in mice. Am J Physiol Endocrinol Metab. 2009;297:E1358–65.
99. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich
A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D,
Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S,
Sabolic I, Sendtner M, Koepsell H. Na(+)-D-glucose cotransporter SGLT1 is
pivotal for intestinal glucose absorption and glucose-dependent incretin
secretion. Diabetes. 2012;61:187–96.
100. Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, Mseeh F, Shadoan
MK, Sands A, Zambrowicz B, Ding Z-M. LX4211 increases serum glucagon-
like peptide 1 and peptide YY levels by reducing sodium/glucose
cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J
Pharmacol Exp Ther. 2013;345:250–9.
101. Zambrowicz B, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Boehm KA,
Ruff D, Powell D, Sands A. Effects of LX4211, a dual sodium-dependent
glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin,
glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing
study in healthy subjects. Clin Ther. 2013;35:1162–73. e8.
102. Zambrowicz B, Ding Z-M, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J,
Smith M, Ruff D, Sands A, Powell D. Effects of LX4211, a dual SGLT1/SGLT2
inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control
in type 2 diabetes. Clin Ther. 2013;35:273–85. e7.
103. Karaki S-I, Tazoe H, Hayashi H, Kashiwabara H, Tooyama K, Suzuki Y,
Kuwahara A. Expression of the short-chain fatty acid receptor, GPR43, in the
human colon. J Mol Histol. 2008;39:135–42.
104. Tazoe H, Otomo Y, Karaki S-I, Kato I, Fukami Y, Terasaki M, Kuwahara A.
Expression of short-chain fatty acid receptor GPR41 in the human colon.
Biomed Res. 2009;30:149–56.
105. Le Poul E, Loison C, Struyf S, Springael J-Y, Lannoy V, Decobecq M-E,
Brezillon S, Dupriez V, Vassart G, Van Damme J, Parmentier M, Detheux M.
Functional characterization of human receptors for short chain fatty
acids and their role in polymorphonuclear cell activation. J Biol Chem.
2003;278:25481–9.
106. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D,
Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC,
Steplewski KM, Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S,
Ignar DM, Foord SM, Wise A, Dowell SJ. The Orphan G protein-coupled
receptors GPR41 and GPR43 are activated by propionate and other short
chain carboxylic acids. J Biol Chem. 2003;278:11312–9.107. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid
receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty
acids. Biochem Biophys Res Commun. 2003;303:1047–52.
108. Nøhr MK, Pedersen MH, Gille A, Egerod KL, Engelstoft MS, Husted AS,
Sichlau RM, Grunddal KV, Poulsen SS, Han S, Jones RM, Offermanns S,
Schwartz TW. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain
fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2
in enteric leukocytes. Endocrinology. 2013;154:3552–64.
109. Akiba Y, Inoue T, Kaji I, Higashiyama M, Narimatsu K, Iwamoto K, Watanabe
M, Guth PH, Engel E, Kuwahara A, Kaunitz JD. Short-chain fatty acid sensing
in rat duodenum. J Physiol. 2015;593:585–99.
110. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells
and mediates free fatty acid stimulation of incretin secretion. Diabetes.
2008;57:2280–7.
111. Hauge M, Vestmar MA, Husted AS, Ekberg JP, Wright MJ, Di Salvo J, Weinglass
AB, Engelstoft MS, Madsen AN, Lückmann M, Miller MW, Trujillo ME, Frimurer TM,
Holst B, Howard AD, Schwartz TW. GPR40 (FFAR1) - Combined Gs and Gq
signaling in vitro is associated with robust incretin secretagogue action ex vivo
and in vivo. Mol Metab. 2015;4:3–14.
112. Leech CA, Habener JF. Regulation of Glucagon-Like Peptide-1 Receptor and
Calcium-Sensing Receptor Signaling by l-Histidine. Endocrinology.
2013;144:4851–8.
113. Mace OJ, Schindler M, Patel S. The regulation of K- and L-cell activity by
GLUT2 and the calcium-sensing receptor CasR in rat small intestine. J
Physiol. 2012;590(Pt 12):2917–36.
114. Diakogiannaki E, Pais R, Tolhurst G, Parker HE, Horscroft J, Rauscher B, Zietek T,
Daniel H, Gribble FM, Reimann F. Oligopeptides stimulate glucagon-like
peptide-1 secretion in mice through proton-coupled uptake and the calcium-
sensing receptor. Diabetologia. 2013;56:2688–96.
115. Joshi S, Tough IR, Cox HM. Endogenous PYY and GLP-1 mediate l-glutamine
responses in intestinal mucosa. Br J Pharmacol. 2013;170:1092–101.
116. Pais R, Gribble FM, Reimann F. Signalling pathways involved in the
detection of peptones by murine small intestinal enteroendocrine L-cells.
Peptides. 2015;77:9–15.
117. Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing
mechanism contributing to Glucagon-Like Peptide-1 Secretion from the
GLUTag cell line. Diabetes. 2003;52:1147–54.
118. Mortensen PB, Holtug K, Rasmussen HS. Short-chain fatty acid production from
mono- and disaccharides in a fecal incubation system: implications for colonic
fermentation of dietary fiber in humans. J Nutr. 1988;118(April):321–5.
119. Titgemeyer E, Bourquin L, Fahey GCJ, Garleb K. Fermentability of various fiber
sources by human fecal bacteria in vitro. Am J Clin Nutr. 1991;53:1418–24.
120. Bourquin LD, Titgemeyer EC, Fahey GC. Fermentation of various dietary
fiber sources by human fecal bacteria. Nutr Res. 1996;16:1119–31.
121. Velázquez M, Davies C, Marett R, Slavin JL, Feirtag JM. Effect of
Oligosaccharides and fibre substitutes on short-chain fatty acid production
by Human Faecal Microflora. Anaerobe. 2000;6:87–92.
122. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short
chain fatty acids in human large intestine, portal, hepatic and venous blood.
Gut. 1987;28:1221–7.
123. Weaver GA, Krause JA, Miller TL, Wolin MJ. Short chain fatty acid
distributions of enema samples from a sigmoidoscopy population: an
association of high acetate and low butyrate ratios with adenomatous
polyps and colon cancer. Gut. 1988;29:1539–43.
124. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E,
Cameron J, Grosse J, Reimann F, Gribble FM. Short-chain fatty acids
stimulate glucagon-like peptide-1 secretion via the G-protein-coupled
receptor FFAR2. Diabetes. 2012;61:364–71.
125. Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC,
Ghatei MA, Bloom SR, Frost G. The short chain fatty acid propionate
stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents.
Int J Obes (Lond). 2015;39:424–9.
126. Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese
SEK, MacDougall K, Preston T, Tedford C, Finlayson GS, Blundell JE, Bell JD,
Thomas EL, Mt-Isa S, Ashby D, Gibson GR, Kolida S, Dhillo WS, Bloom SR,
Morley W, Clegg S, Frost G. Effects of targeted delivery of propionate to the
human colon on appetite regulation, body weight maintenance and
adiposity in overweight adults. Gut. 2015;64:1744–54.
127. Berggren AM, Björck IME, Nyman EMGL, Eggum BO. Short-chain fatty
acid content and pH in caecum of rats given various sources of
carbohydrates. J Sci Food Agric. 1993;63:397–406.
Bodnaruc et al. Nutrition & Metabolism  (2016) 13:92 Page 15 of 16128. Jenkins DJ, Vuksan V, Kendall CW, Würsch P, Jeffcoat R, Waring S, Mehling
CC, Vidgen E, Augustin LS, Wong E. Physiological effects of resistant
starches on fecal bulk, short chain fatty acids, blood lipids and glycemic
index. J Am Coll Nutr. 1998;17:609–16.
129. Cani PD, Neyrinck AM, Maton N, Delzenne NM. Oligofructose promotes
satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1.
Obes Res. 2005;13:1000–7.
130. Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, Danna SC,
Tripathy S, Hegsted M, Keenan MJ. Dietary resistant starch upregulates total
GLP-1 and PYY in a sustained day-long manner through fermentation in
rodents. Am J Physiol Endocrinol Metab. 2008;295:E1160–6.
131. Cani PD, Joly E, Horsmans Y, Delzenne NM. Oligofructose promotes satiety
in healthy human: a pilot study. Eur J Clin Nutr. 2005;60:567–72.
132. Cani PD, Daubioul CA, Reusens B, Remacle C, Catillon G, Delzenne NM.
Involvement of endogenous glucagon-like peptide-1(7-36) amide on
glycaemia-lowering effect of oligofructose in streptozotocin-treated rats. J
Endocrinol. 2005;185:457–65.
133. Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R.
Improvement of Glucose Tolerance and Hepatic Insulin Sensitivity by
Oligofructose Requires a Functional Glucagon-Like Peptide 1 Receptor.
Diabetes. 2006;55:1484–90.
134. Cani PD, Hoste S, Guiot Y, Delzenne NM. Dietary non-digestible
carbohydrates promote L-cell differentiation in the proximal colon of rats. Br
J Nutr. 2007;98:32–7.
135. Tvrzicka E, Kremmyda L-S, Stankova B, Zak A. Fatty acids as biocompounds:
their role in human metabolism, health and disease–a review. Part 1:
classification, dietary sources and biological functions. Biomed Pap Med Fac
Univ Palacky Olomouc Czech Repub. 2011;155:117–30.
136. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M,
Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut
incretin glucagon-like peptide-1 secretion through GPR120. Nat Med.
2005;11:90–4.
137. Thomsen C, Rasmussen O, Lousen T, Holst JJ, Fenselau S, Schrezenmeir J,
Hermansen K. Differential effects of saturated and monounsaturated fatty
acids on postprandial lipemia and incretin responses in healthy subjects.
Am J Clin Nutr. 1999;69:1135–43.
138. Thomsen C, Storm H, Holst JJ, Hermansen K. Differential effects of saturated
and monounsaturated fats on postprandial lipemia and glucagon-like
peptide 1 responses in patients with type 2 diabetes. Am J Clin Nutr.
2003;77:605–11.
139. Prieto PG, Cancelas J, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ.
Effects of an olive oil-enriched diet on plasma GLP-1 concentration and
intestinal content, plasma insulin concentration, and glucose tolerance in
normal rats. Endocrine. 2005;26:107–15.
140. Cancelas J, Prieto PG, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ.
Effects of an olive oil-enriched diet on glucagon-like peptide 1 release and
intestinal content, plasma insulin concentration, glucose tolerance and
pancreatic insulin content in an animal model of type 2 diabetes. Horm
Metab Res. 2006;38:98–105.
141. Paniagua JA, de la Sacristana AG, Sánchez E, Romero I, Vidal-Puig A, Berral FJ,
Escribano A, Moyano MJ, Peréz-Martinez P, López-Miranda J, Pérez-Jiménez F. A
MUFA-rich diet improves posprandial glucose, lipid and GLP-1 responses in
insulin-resistant subjects. J Am Coll Nutr.
2007;26:434–44.
142. Adachi T, Tanaka T, Takemoto K, Koshimizu T, Hirasawa A, Tsujimoto G.
Free fatty acids administered into the colon promote the secretion of
glucagon-like peptide-1 and insulin. Biochem Biophys Res Commun.
2006;340:332–7.
143. Tanaka T, Yano T, Adachi T, Koshimizu T, Hirasawa A, Tsujimoto G. Cloning
and characterization of the rat free fatty acid receptor GPR120: in vivo effect
of the natural ligand on GLP-1 secretion and proliferation of pancreatic beta
cells. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:515–22.
144. Cheshmehkani A, Senatorov IS, Kandi P, Singh M, Britt A, Hayslett R, Moniri
NH. Fish oil and flax seed oil supplemented diets increase FFAR4 expression
in the rat colon. Inflamm Res. 2015;64:809–15.
145. Veldhorst M, Smeets A, Soenen S, Hochstenbach-Waelen A, Hursel R,
Diepvens K, Lejeune M, Luscombe-Marsh N, Westerterp-Plantenga M.
Protein-induced satiety: effects and mechanisms of different proteins.
Physiol Behav. 2008;94:300–7.
146. Lejeune MP, Westerterp KR, Adam TC, Luscombe-Marsh ND, Westerterp-
Plantenga MS. Ghrelin and glucagon-like peptide 1 concentrations, 24-hsatiety, and energy and substrate metabolism during a high-protein diet
and measured in a respiration chamber. Am J Clin Nutr. 2006;83:89–94.
147. Smeets AJ, Soenen S, Luscombe-Marsh ND, Ueland O, Westerterp-Plantenga
MS. Energy Expenditure, Satiety, and Plasma Ghrelin, Glucagon-Like Peptide
1, and Peptide Tyrosine-Tyrosine Concentrations following a Single High-
Protein Lunch. J Nutr. 2008;138:698–702.
148. Oya M, Kitaguchi T, Pais R, Reimann F, Gribble F, Tsuboi T. The G protein-
coupled receptor family C group 6 subtype A (GPRC6A) receptor is involved
in amino acid-induced glucagon-like peptide-1 secretion from GLUTag cells.
J Biol Chem. 2013;288:4513–21.
149. Dworatzek PD, Arcudi K, Gougeon R, Husein N, Sievenpiper JL, Williams SL.
Nutrition therapy. Can J Diabetes. 2013;37 Suppl 1:S45–55.
150. American Diabetes Association. 3. Foundations of Care and Comprehensive
Medical Evaluation. Diabetes Care. 2015;39(Supplement 1):S23–35.
151. Rebello CJ, Johnson WD, Martin CK, Xie W, O’Shea M, Kurilich A,
Bordenave N, Andler S, van Klinken BJW, Chu Y-F, Greenway FL.
Acute effect of oatmeal on subjective measures of appetite and satiety
compared to a ready-to-eat breakfast cereal: a randomized crossover
trial. J Am Coll Nutr. 2013;32:272–9.
152. Rebello CJ, Johnson WD, Martin CK, Han H, Chu Y-F, Bordenave N. Instant
Oatmeal Increases Satiety and Reduces Energy Intake Compared to a
Ready-to-Eat Oat-Based Breakfast Cereal: A Randomized Crossover Trial. J
Am Coll Nutr. 2016;35:41–9.
153. Kendall CWC, Josse a R, Esfahani a, Jenkins DJ a. The impact of pistachio
intake alone or in combination with high-carbohydrate foods on post-
prandial glycemia. Eur J Clin Nutr. 2011;65:696–702.
154. Kendall CWC, West SG, Augustin LS, Esfahani a, Vidgen E, Bashyam B,
Sauder K a, Campbell J, Chiavaroli L, Jenkins a L, Jenkins DJ. Acute
effects of pistachio consumption on glucose and insulin, satiety
hormones and endothelial function in the metabolic syndrome.
Eur J Clin Nutr. 2014;68:370–5.
155. Parham M, Heidari S, Khorramirad A, Hozoori M, Hosseinzadeh F, Bakhtyari L,
Vafaeimanesh J. Effects of Pistachio Nut Supplementation on Blood Glucose
in Patients with Type 2 Diabetes: A Randomized Crossover Trial. Rev Diabet
Stud. 2014;11:190–6.
156. Jenkins DJ a, Kendall CWC, Josse AR, Salvatore S, Brighenti F, Augustin LS a, Ellis
PR, Vidgen E, Rao a V. Almonds decrease postprandial glycemia, insulinemia, and
oxidative damage in healthy individuals. J Nutr. 2006;136:2987–92.
157. Jenkins DJ a, Kendall CWC, Marchie A, Josse AR, Nguyen TH, Faulkner D a,
Lapsley KG, Singer W. Effect of almonds on insulin secretion and insulin
resistance in nondiabetic hyperlipidemic subjects: a randomized controlled
crossover trial. Metabolism. 2008;57:882–7.
158. Cohen AE, Johnston CS. Almond ingestion at mealtime reduces postprandial
glycemia and chronic ingestion reduces hemoglobin A1c in individuals with
well-controlled type 2 diabetes mellitus. Metabolism. 2011;60:1312–7.
159. Mori AM, Considine RV, Mattes RD. Acute and second-meal effects of
almond form in impaired glucose tolerant adults: a randomized crossover
trial. Nutr Metab (Lond). 2011;8:6.
160. Ratliff J, Leite JO, de Ogburn R, Puglisi MJ, VanHeest J, Fernandez ML.
Consuming eggs for breakfast influences plasma glucose and ghrelin,
while reducing energy intake during the next 24 hours in adult men.
Nutr Res. 2010;30:96–103.
161. Vander Wal JS, Marth JM, Khosla P, Jen K-LC, Dhurandhar NV. Short-term
effect of eggs on satiety in overweight and obese subjects. J Am Coll Nutr.
2005;24:510–5.
162. Pombo-Rodrigues S, Calame W, Re R. The effects of consuming eggs for lunch
on satiety and subsequent food intake. Int J Food Sci Nutr. 2011;62:593–9.
163. Liu a G, Puyau RS, Han H, Johnson WD, Greenway FL, Dhurandhar NV. The
Effect of an Egg Breakfast on Satiety in Children and Adolescents: A
Randomized Crossover Trial. J Am Coll Nutr. 2015;34:1–6.
164. Wien M, Haddad E, Oda K, Sabaté J. A randomized 3 × 3 crossover study to
evaluate the effect of Hass avocado intake on post-ingestive satiety, glucose
and insulin levels, and subsequent energy intake in overweight adults.
Nutr J. 2013;12:155.
165. Freeland KR, Wilson C, Wolever TMS. Adaptation of colonic fermentation and
glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year
in hyperinsulinaemic human subjects. Br J Nutr. 2010;103:82–90.
166. Nilsson AC, Johansson-Boll EV, Björck IME. Increased gut hormones and
insulin sensitivity index following a 3-d intervention with a barley kernel-
based product: a randomised cross-over study in healthy middle-aged
subjects. Br J Nutr. 2015;114:899–907.
Bodnaruc et al. Nutrition & Metabolism  (2016) 13:92 Page 16 of 16167. Josse AR, Kendall CWC, Augustin LSA, Ellis PR, Jenkins DJA. Almonds and
postprandial glycemia-a dose-response study. Metabolism. 2007;56:400–4.
168. Reis CEG, Ribeiro DN, Costa NMB, Bressan J, Alfenas RCG, Mattes RD. Acute
and second-meal effects of peanuts on glycaemic response and appetite in
obese women with high type 2 diabetes risk: a randomised cross-over
clinical trial. Br J Nutr. 2013;109:2015–23.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
